Makindo Medical Notes"One small step for man, one large step for Makindo" |
|
---|---|
Download all this content in the Apps now Android App and Apple iPhone/Pad App | |
MEDICAL DISCLAIMER: The contents are under continuing development and improvements and despite all efforts may contain errors of omission or fact. This is not to be used for the assessment, diagnosis, or management of patients. It should not be regarded as medical advice by healthcare workers or laypeople. It is for educational purposes only. Please adhere to your local protocols. Use the BNF for drug information. If you are unwell please seek urgent healthcare advice. If you do not accept this then please do not use the website. Makindo Ltd. |
Related Subjects: |CEA |ALP |LDH
With effective treatment, the overall five-year survival rate is 97%. Orchidectomy is both diagnostic and therapeutic. For patients desiring future fertility, sperm banking should be discussed early in the course of treatment.
Category | Seminoma | Non-Seminoma |
---|---|---|
Description | A type of germ cell tumour that tends to grow and spread more slowly, typically affecting men aged 30-50. | A group of more aggressive germ cell tumours, including embryonal carcinoma, yolk sac tumour, choriocarcinoma, and teratoma. Often affects younger men (15-35 years). |
LDH Levels | LDH can be elevated in seminoma but is less specific compared to non-seminomas. It may indicate a larger tumour burden. | LDH is often elevated and is used alongside AFP and HCG as a marker for tumour burden and prognosis. Elevated LDH is more common in non-seminomas. |
Other Tumour Markers | HCG can also be elevated, but AFP is typically normal. | AFP, HCG, and LDH are often elevated. These markers help in staging and prognosis. |
Treatment |
|
|
Category | Mixed Germ Cell Tumours | Stromal Tumours | Secondary Testicular Tumours |
---|---|---|---|
Description | Contains both seminoma and non-seminoma elements; behaves like non-seminomas due to the aggressive component. | Rare, non-germ cell tumours such as Leydig cell tumours and Sertoli cell tumours; generally less aggressive but can be malignant. | Metastatic tumours that spread to the testicles from other primary sites, such as lymphoma. |
Clinical Presentation | Presents similarly to non-seminomas due to the aggressive non-seminoma component. | Can present as a painless mass; Leydig cell tumours may produce hormones leading to gynecomastia or precocious puberty. | Symptoms depend on the primary site of cancer but may include a testicular mass, weight loss, or systemic symptoms. |
Diagnostic Tests |
|
|
|
Treatment Options |
|
|
|